Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Newly approved MS drug...

    Newly approved MS drug Mayzent priced at USD 88000: Novartis

    GarimaWritten by Garima Published On 2019-03-28T10:00:00+05:30  |  Updated On 28 March 2019 10:00 AM IST
    Newly approved MS drug Mayzent priced at USD 88000: Novartis

    Novartis has priced the treatment at $88,000 annually, head of pharmaceuticals Paul Hudson told Reuters, a level exceeding some other MS drugs and one that may draw scrutiny from payers.


    ZURICH: Novartis AG has won U.S. Food and Drug Administration approval for multiple sclerosis drug Mayzent as the Swiss company targets patients whose disease advances from intermittent attacks to a gradually worsening condition.


    Novartis has priced the treatment at $88,000 annually, head of pharmaceuticals Paul Hudson told Reuters, a level exceeding some other MS drugs and one that may draw scrutiny from payers.


    Medical Dialogues had earlier reported that the U.S. Food and Drug Administration had approved Novartis’ Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It said the drug’s benefits were not statistically significant in patients with non-active MS.


    Also Read: USFDA approves Novartis’ oral drug Mayzent to treat multiple sclerosis

    In a 1,651-person trial, 26 per cent of patients who got Mayzent saw their disability progress after three months, less than the 32 per cent of patients who got a placebo, amounting to a relative risk reduction of 21 per cent.


    The drug’s cost will likely attract attention, as the independent Boston-based group Institute for Clinical and Economic Review (ICER) has already suggested in a draft report that Mayzent, at the Novartis price, likely far exceeds levels generally thought to be cost-effective.


    “We will find a way to bring it to market, so patients get the best clinical choice,” Hudson said. “I think we’ve been very responsible with the pricing of it.”


    So far, however, ICER has concluded Novartis would have to price Mayzent between $680 and $1,000 per month for it be considered cost-effective.


    Hudson said ICER’s figures could change in its final report, due out in June. “Wait and see how that plays out,” he said, adding Novartis was still working to help people understand Mayzent’s benefits.


    BILLION-DOLLAR BUSINESS


    Novartis’ older Gilenya MS drug, its top seller at $3.34 billion annually, has a list price of $95,594 annually. Roche’s new MS drug, Ocrevus, with 2018 sales of $2.4 billion, lists at $65,000. Novartis sees Mayzent, a synthetic derivative of Gilenya modified to reduce side effects like a slow heart rate and better protect nerves from destruction, as a way to help often-older patients whose disease moves past relapsing MS to a progressively worsening condition.


    Hudson called Mayzent a potential blockbuster with annual sales of more than $1 billion, while revenue is estimated at about $800 million by 2022, according Refinitiv data.


    According to a recent report by Reuters, Stefan Schneider, a Bank Vontobel analyst, forecasts $600 million peak annual sales.



    With Mayzent’s approval for the active form of SPMS, Schneider said that leaves it in competition with existing drugs and puts the onus on Novartis’s marketing force to convince doctors to switch from medicines they know better.

    “Novartis will need to promote SPMS testing and change of therapy, likely not an easy endeavour,” he told Reuters.

    EuropeFDAhealthhealth carehealth newsmayzentmedical newsMedical Regulatory Issuesmultiple sclerosisNovartisoral drugpharmapharma newsPharmaceuticals and Medical Research (TRBC)ScienceSwitzerlandsyndromeUnited KingdomUnited StatesUSUSFDA
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok